$96.04
0.59% today
Nasdaq, Nov 12, 10:00 pm CET
ISIN
NL0011606264
Symbol
MRUS

Merus N.V. Stock price

$96.04
+1.19 1.25% 1M
+53.63 126.46% 6M
+53.99 128.39% YTD
+44.41 86.02% 1Y
+76.88 401.25% 3Y
+82.84 627.58% 5Y
+86.00 856.57% 10Y
+86.00 856.57% 20Y
Nasdaq, Closing price Wed, Nov 12 2025
+0.56 0.59%
ISIN
NL0011606264
Symbol
MRUS
Industry

Key metrics

Basic
Market capitalization
$7.2b
Enterprise Value
$6.6b
Net debt
positive
Cash
$635.9m
Shares outstanding
75.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
127.9 | 131.2
EV/Sales
116.7 | 119.6
EV/FCF
negative
P/B
9.3
Financial Health
Equity Ratio
82.8%
Return on Equity
-33.2%
ROCE
-45.4%
ROIC
-167.2%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$56.6m | $55.2m
EBITDA
$-368.8m | $-386.8m
EBIT
$-371.2m | $-404.1m
Net Income
$-381.1m | $-448.4m
Free Cash Flow
$-317.9m
Growth (TTM | estimate)
Revenue
57.6% | 52.8%
EBITDA
-61.4% | -43.5%
EBIT
-60.7% | -48.5%
Net Income
-55.8% | -108.2%
Free Cash Flow
-102.1%
Margin (TTM | estimate)
Gross
-
EBITDA
-651.5% | -700.4%
EBIT
-655.8%
Net
-673.3% | -812.1%
Free Cash Flow
-561.6%
More
EPS
$-5.0
FCF per Share
$-4.2
Short interest
2.9%
Employees
291
Rev per Employee
$120.0k
Show more

Is Merus N.V. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,033 stocks worldwide.

Merus N.V. Stock Analysis

Unlock Scores for Free

Analyst Opinions

23 Analysts have issued a Merus N.V. forecast:

9x Buy
39%
14x Hold
61%

Analyst Opinions

23 Analysts have issued a Merus N.V. forecast:

Buy
39%
Hold
61%

Financial data from Merus N.V.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
57 57
58% 58%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 99 99
32% 32%
175%
- Research and Development Expense 328 328
71% 71%
580%
-369 -369
61% 61%
-651%
- Depreciation and Amortization 2.45 2.45
2% 2%
4%
EBIT (Operating Income) EBIT -371 -371
61% 61%
-656%
Net Profit -381 -381
56% 56%
-673%

In millions USD.

Don't miss a Thing! We will send you all news about Merus N.V. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Merus N.V. Stock News

Neutral
Seeking Alpha
15 days ago
The market continues to trade deeper in overbought territory based on most traditional valuation metrics. Most of the gains over the past three years have been driven by tech giants riding the AI Revolution higher. Equities continue to hit all-time highs even the government shut down has nearly hit the one month mark and trade tensions remain between China and the U.S.
Neutral
GlobeNewsWire
19 days ago
– 100% response rate in 1L left-sided mCRC (n=8, confirmed and unconfirmed) – 62% response rate in 2L left- and right-sided mCRC (n=13, confirmed and unconfirmed)  UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Merus N.V.
Neutral
Business Wire
20 days ago
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Merus N.V. (NasdaqGM: MRUS) to Genmab A/S (NasdaqGS: GMAB). Under the terms of the proposed transaction, shareholders of Merus will receive $97.00 in cash for each share of Merus that they own. KSF is s...
More Merus N.V. News

Company Profile

Merus NV is a clinical-stage immune-oncology company, which engages in the discovery and development of bi-specific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg on June 16, 2003 and is headquartered in Utrecht, Netherlands.

Head office Netherlands
CEO Bill Lundberg
Employees 291
Founded 2003
Website merus.nl

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today